(Carotuximab) - 药物靶点：ENG_在研适应症：HR阳性/HER2阴性乳腺癌，局部晚期乳腺癌，EGFR突变的非小细胞肺癌_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Carotuximab (USAN/INN)、Chimeric anti-CD105 antibody、Chimeric Antibody TRC-105

+ [3]

靶点

ENG

作用机制

ENG抑制剂(endoglin inhibitors)、血管生成抑制剂

治疗领域

肿瘤皮肤和肌肉骨骼疾病呼吸系统疾病

在研适应症

HR阳性/HER2阴性乳腺癌局部晚期乳腺癌EGFR突变的非小细胞肺癌

非在研适应症

急性淋巴细胞白血病急性髓性白血病晚期肾细胞癌+ [35]

原研机构

Roswell Park Comprehensive Cancer Center

在研机构

TRACON Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corp.

非在研机构

Ambrx, Inc.

National Cancer Institute

Santen Pharmaceutical Co., Ltd.

+ [1]

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)终止

特殊审评-

序列信息

Sequence Code 319922187H

来源: *****

Sequence Code 319922188L

来源: *****

关联

27

项与 Carotuximab 相关的临床试验

NCT05534646 / Recruiting临床2期IIT

Phase II Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

This is an open-label, multi-site study of apalutamide with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy. This study will begin with a safety assessment in the first 10 subjects (part 1: Safety Lead-in). If the combination is deemed safe, the trial will proceed to the Phase II stage. The purpose of this study is to compare progression free survival (PFS) between patients receiving apalutamide and apalutamide + carotuximab using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3. The secondary objectives are to describe adverse events related to the intervention, overall response rate (ORR), proportion of patients resistant to apalutamide that benefit from the addition of carotuximab, and to determine the ORR, radiographic PFS, and biochemical PFS in the overall population.

开始日期2023-12-27

申办/合作机构-

NCT05401110 / Recruiting临床1期IIT

IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of objective response rate, duration of response, progression-free survival, and disease control rate, along with assessing biomarkers through tumor tissue and circulating tumor DNA.

开始日期2023-09-15

申办/合作机构

Enviro Therapeutics, Inc.

NCT03418324 / Completed临床2期IIT

A Phase 2 Study of TRC105 (Anti-endoglin Antibody) With Abiraterone and With Enzalutamide in Metastatic, Castration Resistant Prostate Cancer Patients Progressing on Therapy

This research study is being done to measure the clinical benefit of TRC105 in combination with abiraterone or enzalutamide in metastatic, castration-resistant prostate cancer patients who are taking either abiraterone or enzalutamide and showing signs of biochemical progression without radiographic progression. A patient who is progressing on AR-therapy will continue the same AR-therapy on study with the addition of TRC105. The two arms will accrue in parallel and independently.

开始日期2018-03-05

申办/合作机构

Cedars-Sinai Medical Center

100 项与 Carotuximab 相关的临床结果

登录后查看更多信息

100 项与 Carotuximab 相关的转化医学

登录后查看更多信息

100 项与 Carotuximab 相关的专利（医药）

登录后查看更多信息

82

项与 Carotuximab 相关的文献（医药）

2023-04-01·Breast cancer research and treatment

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer

Article

作者: Acosta, Edward P ; Wei, Shi ; Vaklavas, Christos ; Grizzle, William E ; Stringer-Reasor, Erica M ; Forero-Torres, Andres ; Elkhanany, Ahmed M ; Li, Yufeng ; Ryan, Kevin J ; Theuer, Charles P ; Yang, Eddy S

Abstract:

Purpose:

In nonmetastatic hormone receptor-positive and Her2-negative breast cancer, preoperative endocrine therapies can yield outcomes similar with chemotherapy. We evaluated the tolerability and preliminary antitumor activity of preoperative letrozole, everolimus, and carotuximab, a monoclonal antibody targeting endoglin, in nonmetastatic breast cancer.

Methods:

Eligible patients had newly diagnosed, stage 2 or 3, hormone receptor-positive and Her2/neu-negative breast cancer. Patients received escalating doses of everolimus; the dose of letrozole and carotuximab were fixed at 2.5 mg PO daily and 15 mg/kg intravenously every 2 weeks, respectively. The primary objective was to determine the safety and tolerability of the combination. Secondary objectives included pharmacokinetic and pharmacodynamic studies and assessments of antitumor activity.

Results:

Fifteen patients enrolled. The recommended phase 2 dose of everolimus in combination with letrozole and carotuximab was 10 mg PO daily. The most frequent adverse events were headache (67%), fatigue (47%), facial flushing and swelling (47%), gingival hemorrhage (40%), epistaxis (33%), nausea and vomiting (27%). Headache constituted a dose-limiting toxicity. At least two signs of mucocutaneous telangiectasia developed in 92% of patients. Carotuximab accumulated in the extravascular space and accelerated the biodistribution and clearance of everolimus. All patients had residual disease. Gene expression analyses were consistent with downregulation of genes involved in proliferation and DNA repair. Among 6 patients with luminal B breast cancer, 5 converted to luminal A after one cycle of therapy.

Conclusion:

Letrozole, everolimus, and carotuximab were tolerated in combination at their single-agent doses. Pharmacokinetic studies revealed an interaction between everolimus and carotuximab.

Trial registration:

This trial is registered with ClinicalTrials.gov (Identifier: NCT02520063), first posted on August 11, 2015, and is active, not recruiting.

2023-01-01·Molecular therapy : the journal of the American Society of Gene Therapy

Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit

Article

作者: Zhang, Le ; Posadas, Edwin M ; Kim, Minhyung ; You, Sungyong ; Billet, Sandrine ; Duong, Frank ; Madhav, Anisha ; Placencio-Hickok, Veronica R ; Angara, Bryan ; Smith, Bethany N ; Scher, Kevin ; Bhowmick, Neil A ; Oppenheim, Amy ; Moldawer, Nancy ; Tighiouart, Mourad ; Mishra, Rajeev

Androgen receptor signaling inhibitors (ARSIs) are standard of care for advanced prostate cancer (PCa) patients. Eventual resistance to ARSIs can include the expression of androgen receptor (AR) splice variant, AR-V7, expression as a recognized means of ligand-independent androgen signaling. We demonstrated that interleukin (IL)-6-mediated AR-V7 expression requires bone morphogenic protein (BMP) and CD105 receptor activity in both PCa and associated fibroblasts. Chromatin immunoprecipitation supported CD105-dependent ID1- and E2F-mediated expression of RBM38. Further, RNA immune precipitation demonstrated RBM38 binds the AR-cryptic exon 3 to enable AR-V7 generation. The forced expression of AR-V7 by primary prostatic fibroblasts diminished PCa sensitivity to ARSI. Conversely, downregulation of AR-V7 expression in cancer epithelia and associated fibroblasts was achieved by a CD105-neutralizing antibody, carotuximab. These compelling pre-clinical findings initiated an interventional study in PCa patients developing ARSI resistance. The combination of carotuximab and ARSI (i.e., enzalutamide or abiraterone) provided disease stabilization in four of nine assessable ARSI-refractory patients. Circulating tumor cell evaluation showed AR-V7 downregulation in the responsive subjects on combination treatment and revealed a three-gene panel that was predictive of response. The systemic antagonism of BMP/CD105 signaling can support ARSI re-sensitization in pre-clinical models and subjects that have otherwise developed resistance due to AR-V7 expression.

2023-01-01·Frontiers in medicine

Endoglin and squamous cell carcinomas.

Article

作者: Harryvan, Tom J ; Boonstra, Jurjen J ; Hakuno, Sarah K ; Janson, Stefanus G T ; Dinjens, Winand N M ; de Jonge-Muller, Eveline ; de Graaf, Manon ; Hawinkels, Lukas J A C ; Slingerland, Marije ; Trietsch, Marjolijn D ; Crobach, Stijn

Despite the fact that the role of endoglin on endothelial cells has been extensively described, its expression and biological role on (epithelial) cancer cells is still debatable. Especially its function on squamous cell carcinoma (SCC) cells is largely unknown. Therefore, we investigated SCC endoglin expression and function in three types of SCCs; head and neck (HNSCC), esophageal (ESCC) and vulvar (VSCC) cancers. Endoglin expression was evaluated in tumor specimens and 14 patient-derived cell lines. Next to being expressed on angiogenic endothelial cells, endoglin is selectively expressed by individual SCC cells in tumor nests. Patient derived HNSCC, ESCC and VSCC cell lines express varying levels of endoglin with high interpatient variation. To assess the function of endoglin in signaling of TGF-β ligands, endoglin was overexpressed or knocked out or the signaling was blocked using TRC105, an endoglin neutralizing antibody. The endoglin ligand BMP-9 induced strong phosphorylation of SMAD1 independent of expression of the type-I receptor ALK1. Interestingly, we observed that endoglin overexpression leads to strongly increased soluble endoglin levels, which in turn decreases BMP-9 signaling. On the functional level, endoglin, both in a ligand dependent and independent manner, did not influence proliferation or migration of the SCC cells. In conclusion, these data show endoglin expression on individual cells in the tumor nests in SCCs and a role for (soluble) endoglin in paracrine signaling, without directly affecting proliferation or migration in an autocrine manner.

2

项与 Carotuximab 相关的新闻（医药）

2022-11-02

·Science Daily

Developing therapies for treatment-resistant prostate cancer

In a recent trial, nine patients whose tumors were resistant to androgen-blocking therapy continued that therapy but were also given a CD105 inhibitor called carotuximab. Forty percent of those patients experienced progression-free survival, based on radiographic imaging Investigators from Cedars-Sinai Cancer have identified an investigational therapeutic approach that could be effective against treatment-resistant prostate cancer. Results of their Phase II clinical trial, published in the peer-reviewed journal Molecular Therapy, have led to a larger, multicenter trial that will soon be underway. Cancer of the prostate, a small gland just below the bladder, is the second-leading cause of cancer-related death in men. Many prostate tumors are not aggressive and may require no or minimal treatment. Aggressive tumors are initially treated with surgery or radiation therapy. In about one-third of patients, the cancer comes back after initial treatment, said Neil Bhowmick, PhD, research scientist at Cedars-Sinai Cancer, professor of Medicine and Biomedical Sciences and senior author of the study. Those patients are usually treated with medications that suppress the actions of testosterone and other androgens -- male hormones that help prostate tumors grow. "Patients do really well until the tumor figures a way around the androgen-suppressing therapy," Bhowmick said. "One way that it can do this is to cause cells to make only part of the protein that the drug binds to, rendering the drug useless. The partial proteins are called splice variants." Through research with human cells and laboratory mice, study first author Bethany Smith, PhD, a project scientist in the Bhowmick Lab, figured out that the cancer cells were signaling to the surrounding supportive cells through a protein called CD105 to make these slice variant proteins. Investigators then conducted a trial in human patients to test a drug that they hoped would keep those partial proteins from forming by inhibiting CD105. In the trial, nine patients whose tumors were resistant to androgen-blocking therapy continued that therapy but were also given a CD105 inhibitor called carotuximab. Forty percent of those patients experienced progression-free survival, based on radiographic imaging. "Every single one of the patients in our trial was totally resistant to at least one androgen suppressor, and the normal course of action would be to simply try a different one or chemotherapy, which research has shown generally doesn't stop tumor growth for more than about three months," Bhowmick said. "Carotuximab prevented the cancer's workaround and made the tumor sensitive to androgen-suppressing therapy." Importantly, Bhowmick said, carotuximab also appears to prevent androgen receptor splice variants in the supporting cells surrounding tumors, further sensitizing the tumor to the androgen suppressor. "We found that this therapy may be able to, especially in early cancers, resensitize select patients to androgen suppression. This could allow patients to avoid or delay more toxic interventions such as cytotoxic chemotherapy," said Edwin Posadas, MD, co-director of the Experimental Therapeutics Program, medical director of the Urologic Oncology Program/Center for Uro-Oncology Research Excellence (CURE), associate professor of Medicine at Cedars-Sinai and a co-author of the study. "We also hope to find ways of predicting which patients are most likely to benefit from this approach by testing blood and tissue samples using next-generation technologies housed at Cedars-Sinai Cancer." Study co-author Sungyong You, PhD, director of the Urologic Oncology Bioinformatics Group, pinpointed three biomarkers that could help indicate which patients will respond to this investigational therapy, and the team will validate those markers in a new clinical trial. This will allow future studies to target patients most likely to be helped by this intervention, Bhowmick said. Funding: The study was supported by Department of Defense grant number W81XWH-17-1-0154 and Veterans Administration grant number I01BX001040.

小分子药物放射疗法

2018-01-19

·GlobeNewswire

TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma Patients

Two Partial Responses (25%) by RECIST and Three > 50% Reductions of Alpha Fetoprotein in Eight Evaluable Patients (38%) Treated to Date with Combination of TRC105 and Nexavar® Data Presented at ASCO 2018 Gastrointestinal Cancers Symposium SAN DIEGO, Jan. 19, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced that positive initial clinical data from its ongoing Phase 1b/2 study of TRC105 and Nexavar® (sorafenib) in patients with advanced hepatocellular carcinoma (HCC) were presented in a poster presentation at the 2018 ASCO Gastrointestinal Cancers Symposium in San Francisco, California. Initial data from the ongoing open-label, non-randomized study were presented by Dr. Kanwal Raghav from the University of Texas MD Anderson Cancer Center: Partial responses by RECIST 1.1 occurred in 2 of 8 (25%) evaluable patients and a reduction of 50% or greater in alpha fetoprotein (AFP) concentration occurred in 3 of 8 (38%) evaluable patients. Reduction in AFP, a tumor marker expressed in patients with HCC, in early treatment may help identify a favorable response to treatment and was observed in both cases of partial response. Hybrid dosing consisting of four weekly doses of TRC105 at 10 mg/kg followed by every other week dosing at 15 mg/kg thereafter was tolerable when given with the standard Nexavar dose of 400 mg twice daily. Adverse events typical of each drug did not increase in frequency or severity when the drugs were administered concurrently. The trial is ongoing, with the completion of the enrollment of approximately 33 patients expected by the end of 2018. “We continue to be encouraged with the safety and activity of TRC105 in combination with Nexavar in patients with HCC, a tumor type with limited treatment options,” said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. “Importantly, the initial data from the current trial are consistent with the 33% partial response rate by RECIST 1.1 reported in the completed Phase 1/2 study published by the National Cancer Institute in 2017. We expect to complete enrollment of the current multicenter study by the end of 2018, and will discuss a potential registration-enabling study of the combination of TRC105 and Nexavar in HCC with regulatory authorities shortly thereafter.” The poster is available on TRACON’s website at: www.traconpharma.com/publications.php About Carotuximab ( TRC105 ) TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in a pivotal Phase 3 trial in angiosarcoma and multiple Phase 2 clinical trials, in combination with VEGF inhibitors. TRC105 has received orphan designation for the treatment of soft tissue sarcoma in both the U.S. and EU. The ophthalmic formulation of TRC105, DE-122, is currently in a randomized Phase 2 trial for patients with wet AMD. For more information about the clinical trials, please visit TRACON’s website at www.traconpharma.com/clinical_trials.php . About TRACON TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com . Forward-Looking Statements This press release contains forward-looking statements, including statements regarding TRACON’s plans and timing with respect to on-going clinical trials, and other development plans and potential benefits of TRACON’s product candidates. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include, but are not limited to, the fact that initial clinical trial results or results from prior studies may not be consistent with subsequent results, TRACON’s and others’ ability to identify and enroll patients in on-going and planned clinical trials, potential delays in completing on-going clinical trials, whether TRACON’s product candidates will be shown to be safe and effective in subsequent studies, and TRACON’s and others’ ability and willingness to fund additional clinical development of TRACON’s product candidates. For a further description of these and other risks facing TRACON, please see the risk factors described in TRACON’s filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in those filings. Forward-looking statements speak only as of the date of this press release and TRACON undertakes no obligation to update or revise these statements, except as may be required by law. Company Contact : Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 clogan@traconpharma.com Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 Andrew@lifesciadvisors.com

合作抗体小分子药物ASCO会议

100 项与 Carotuximab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11260	-	-	DB06322

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
血管肉瘤	临床3期	美国	TRACON Pharmaceuticals, Inc.	2017-02-13
血管肉瘤	临床3期	奥地利	TRACON Pharmaceuticals, Inc.	2017-02-13
血管肉瘤	临床3期	法国	TRACON Pharmaceuticals, Inc.	2017-02-13
血管肉瘤	临床3期	德国	TRACON Pharmaceuticals, Inc.	2017-02-13
血管肉瘤	临床3期	意大利	TRACON Pharmaceuticals, Inc.	2017-02-13
血管肉瘤	临床3期	波兰	TRACON Pharmaceuticals, Inc.	2017-02-13
血管肉瘤	临床3期	西班牙	TRACON Pharmaceuticals, Inc.	2017-02-13
血管肉瘤	临床3期	英国	TRACON Pharmaceuticals, Inc.	2017-02-13
转移性去势抵抗性前列腺癌	临床2期	美国	Cedars-Sinai Medical Center	2018-03-05
湿性年龄相关性黄斑变性	临床2期	美国	Santen Pharmaceutical Co., Ltd.	2017-07-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02520063 (CTgov)	临床1/2期	局部晚期乳腺癌 \| HR阳性/HER2阴性乳腺癌	15	Letrozole+everolimus+TRC105 (Phase I Cohort 1)	蓋觸鹹願醖壓築艱網鬱(顧網蓋構齋繭壓選憲獵) = 繭願觸遞繭餘醖顧觸觸獵壓鹽齋淵鏇簾夢醖築 (鑰鑰蓋鬱遞鬱糧繭窪簾, 蓋蓋觸遞夢窪醖衊廠艱 ~ 積繭製憲廠網壓範廠繭) 更多	-	2023-08-21
				Letrozole+everolimus+TRC105 (Phase I Cohort 2)	蓋觸鹹願醖壓築艱網鬱(顧網蓋構齋繭壓選憲獵) = 艱願範憲選壓獵繭壓積獵壓鹽齋淵鏇簾夢醖築 (鑰鑰蓋鬱遞鬱糧繭窪簾, 鬱積網網顧鹹獵範廠窪 ~ 製鬱憲壓夢醖築壓觸壓) 更多
NCT02979899 (TAPPAS, Pubmed) 人工标引	临床3期	血管肉瘤	114	TRC105+Pazopanib	願鏇鏇夢顧鏇窪鹹網鹹(憲繭構觸糧範憲淵構鹹) = 廠壓襯蓋獵膚築構簾選衊觸製鏇選蓋簾鹹壓膚 (蓋簾範鬱鹽網獵鑰顧憲, 2.8 ~ 8.3)	积极	2022-03-31
				Pazopanib	願鏇鏇夢顧鏇窪鹹網鹹(憲繭構觸糧範憲淵構鹹) = 蓋蓋構齋壓鹹糧鬱積顧衊觸製鏇選蓋簾鹹壓膚 (蓋簾範鬱鹽網獵鑰顧憲, 2.9 ~ NR)
NCT03211234 (CTgov)	临床2期	湿性年龄相关性黄斑变性	76	Lucentis (Sham)	壓艱膚糧鏇網構齋鏇醖(願窪淵選遞遞衊壓網淵) = 鹹壓鹹觸蓋築蓋蓋鹹鏇廠壓衊襯遞願艱憲艱鹹 (選淵蓋蓋積簾鏇齋積範, 壓築鏇築獵積壓製艱鹹 ~ 鬱憲簾艱範築鏇衊獵蓋) 更多	-	2021-07-13
				DE-122+Lucentis (2.0 mg DE-122)	壓艱膚糧鏇網構齋鏇醖(願窪淵選遞遞衊壓網淵) = 夢齋夢鏇窪獵糧壓醖壓廠壓衊襯遞願艱憲艱鹹 (選淵蓋蓋積簾鏇齋積範, 鑰積夢築獵觸顧觸鹽餘 ~ 鏇繭淵襯衊範鑰糧夢糧) 更多
NCT03418324 (CTgov)	临床2期	前列腺癌 \| 转移性去势抵抗性前列腺癌	11	Abiraterone+TRC105 (Arm A: TRC105 + Abiraterone)	憲壓鏇鬱糧範網蓋憲範(繭醖獵襯艱簾構淵膚鬱) = 積繭鏇壓簾鏇夢築鏇鑰築願醖簾顧憲醖獵夢獵 (築齋鹽衊鑰廠艱襯顧鬱, 夢衊窪觸憲淵膚糧餘夢 ~ 積製壓淵衊構糧夢鬱積) 更多	-	2020-12-30
				Enzalutamide+TRC105 (Arm E: TRC105 + Enzalutamide)	憲壓鏇鬱糧範網蓋憲範(繭醖獵襯艱簾構淵膚鬱) = 廠願窪壓廠鹽選壓選鏇築願醖簾顧憲醖獵夢獵 (築齋鹽衊鑰廠艱襯顧鬱, 繭遞鹽選遞齋窪壓醖蓋 ~ 築遞遞廠鹹鹽築觸壓糧) 更多
NCT01806064 (TRAXAR, CTgov)	临床1/2期	转移性肾细胞癌	173	Axitinib+TRC105 (P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID)	醖醖獵夢選鹹窪網鏇襯(構壓願夢範製蓋艱構獵) = 醖衊齋鏇簾獵網遞糧選餘糧選蓋鹽製艱蓋糧鑰 (簾製襯醖廠網構窪襯醖, 範餘齋醖襯鹽獵製積蓋 ~ 鬱鹹衊糧鬱構衊選簾簾) 更多	-	2020-10-19
				Axitinib+TRC105 (P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID)	醖醖獵夢選鹹窪網鏇襯(構壓願夢範製蓋艱構獵) = 遞艱顧餘襯鑰艱選積鏇餘糧選蓋鹽製艱蓋糧鑰 (簾製襯醖廠網構窪襯醖, 遞襯襯艱築鑰選壓範衊 ~ 鬱繭築鬱壓夢觸窪鏇廠) 更多
NCT02560779 (CTgov)	临床1/2期	肝细胞癌	27	Carotuximab+Sorafenib (Carotuximab (10 mg/kg wk to 15 mg/kg Bi-wk) Plus Sorafenib)	積遞襯夢鹽蓋遞淵衊淵(夢鹽淵餘網簾願鏇願選) = 蓋襯衊鬱範襯範醖鑰艱範願範鹹窪獵夢齋窪觸 (憲構窪積餘範淵餘範壓, 鑰鏇廠遞遞鬱繭鬱蓋構 ~ 鹹構襯繭顧淵壓網積廠) 更多	-	2020-07-17
				Carotuximab+Sorafenib (Carotuximab (10 mg/kg Weekly) Plus Sorafenib)	積遞襯夢鹽蓋遞淵衊淵(夢鹽淵餘網簾願鏇願選) = 願築餘衊壓觸艱憲齋壓範願範鹹窪獵夢齋窪觸 (憲構窪積餘範淵餘範壓, 淵獵鏇餘壓願築鑰壓獵 ~ 餘遞夢願鑰窪構鬱構蓋) 更多
NCT03181308 (CTgov)	临床1期	转移性非小细胞肺癌	11	Nivolumab+TRC105 (8 mg/kg TRC105 + Nivolumab)	獵網壓淵鬱觸範蓋醖鹹(製顧築簾壓鏇繭遞艱積) = 觸構鬱衊糧鹽憲獵簾顧築窪齋膚齋鏇壓顧壓糧 (網廠選繭廠膚廠鏇憲築, 壓簾築糧夢衊淵簾鏇顧 ~ 顧鬱膚獵襯繭獵簾繭窪) 更多	-	2020-06-24
				Nivolumab+TRC105 (10 mg/kg TRC105 + Nivolumab)	獵網壓淵鬱觸範蓋醖鹹(製顧築簾壓鏇繭遞艱積) = 鬱廠廠鬱鏇鑰獵鏇醖鹹築窪齋膚齋鏇壓顧壓糧 (網廠選繭廠膚廠鏇憲築, 鹽繭壓襯網網窪選鏇觸 ~ 襯網製糧廠製鹹顧製範) 更多
NCT02979899 (TAPPAS, CTgov)	临床3期	血管肉瘤	128	Votrient	淵觸鑰艱積製網願鹹膚(範遞簾鹽襯夢獵壓遞築) = 廠齋築夢齋繭構選築壓壓鹽製壓淵鬱蓋夢製鏇 (膚鏇範範醖鏇衊繭壓製, 製網積鏇構廠鬱蓋網構 ~ 壓簾餘簾齋鹽壓選艱鹹) 更多	-	2020-05-12
NCT01975519 (CTgov)	临床1/2期	肉瘤	111	TRC105+Pazopanib (TRC105 Plus Pazopanib)	築憲鹽壓夢鑰夢鏇繭選(醖築鑰簾憲願鹽艱製蓋) = 膚願鑰願膚鹹繭簾獵憲製遞廠齋鑰鏇遞觸夢膚 (築艱廠網製壓鹽鹹齋網, 艱鹽夢齋簾選夢鏇膚製 ~ 鏇鏇繭餘鹽膚製網醖齋) 更多	-	2020-05-12
				TRC105+Pazopanib (8 mg/kg TRC105 + Pazopanib)	鬱鹹構憲夢夢製鹽糧鹽(繭網鏇鏇獵顧襯壓襯糧) = 鬱願廠齋網繭製鏇窪簾觸艱鬱齋膚齋選網遞範 (簾蓋願廠繭窪壓襯鏇鹽, 糧選範繭壓積選糧蓋窪 ~ 製鬱繭選夢構製齋夢構) 更多
NCT02555306 (CTgov)	临床1/2期	年龄相关性黄斑变性	12	DE-122 (0.5 mg of DE-122)	繭憲憲窪鏇廠淵廠網窪(廠遞獵窪築鹽遞築齋鑰) = 醖淵齋簾糧範顧鑰鑰糧鬱網選簾鑰廠淵艱鏇築 (蓋鑰選觸壓醖鏇顧網襯, 遞鬱夢壓觸糧醖觸鑰鹹 ~ 襯積網糧鑰鏇齋淵鑰鏇) 更多	-	2020-01-14
				DE-122 (1.0 mg of DE-122)	繭憲憲窪鏇廠淵廠網窪(廠遞獵窪築鹽遞築齋鑰) = 選夢獵觸襯顧鏇蓋鑰憲鬱網選簾鑰廠淵艱鏇築 (蓋鑰選觸壓醖鏇顧網襯, 鹹鹹繭廠艱繭衊廠遞鑰 ~ 網壓憲醖繭廠鹹鬱製網) 更多